 | | | | Related Healthscout Videos | |
|
Page: << Prev | 1 | 2 But in an editorial, Dr. Ron Waksman, of Washington Hospital Center, Washington, D.C., was more cautious. "Before we become overly enthused with new-generation drug-eluting stents, we should call for new-generation trial designs that will enable us to assess whether or not these new stents are necessarily better," he wrote.
The study, which was expected to be presented Monday at the European Society of Cardiology meeting in Munich, was funded by the maker of the biolimus stent, Biosensors Europe SA, Switzerland.
More information
Text Continues Below
There's more on stents and stenting at the American Heart Association.
Page: << Prev | 1 | 2
-- E.J. Mundell
|
.gif)
